Esperion (ESPR)

Company Description

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, once-daily, oral therapies to lower levels of low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is “patient-friendly, physician-friendly, and payer-friendly”.

COMPANY ADDRESS
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108

COMPANY PHONE
734-887-3903

COMPANY WEBSITE



Get BioInvest's perspective on Esperion's CEO


Latest Company News

Esperion Therapeutics Inc. (ESPR) Moves Higher on Volume Spike for June 27 Equities.com - 1 hour ago Esperion Therapeutics Inc. (ESPR) traded on unusually high volume on Jun. 27, as the stock gained 2.03% to close at $43.74. Esperion Therapeutics (ESPR) Reports FDA Confirmation of Regulatory Pathway to ... - StreetInsider.com Stifel Nicolaus Kept Esperion Therapeutics (NDAQ:ESPR) As a “Buy”; They Now ... - Weekly Register [...]
Tue, Jun 27, 2017 9:30:00 PM, Continue reading at the source
Technicals At the Forefront For Esperion Therapeutics Inc (ESPR) Baxter Review - 5 hours ago Looking at shares from a technical standpoint, Esperion Therapeutics Inc (ESPR) presently has a 14-day Commodity Channel Index (CCI) of 115.83. [...]
Tue, Jun 27, 2017 5:03:00 PM, Continue reading at the source
Active Runner in Focus: Esperion Therapeutics Inc (ESPR) Union Trade Journal - 5 hours ago Shares of Esperion Therapeutics Inc (ESPR) is moving on volatility today 2.96% or 1.27 rom the open. The NASDAQ listed company saw a recent bid of 44.14 on 885779 volume. [...]
Tue, Jun 27, 2017 4:52:00 PM, Continue reading at the source
Esperion Therapeutics, Inc. (NasdaqGM:ESPR) Valuation in the Spotlight Concord Register - 7 hours ago Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has an ERP5 rank of 15192. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. [...]
Tue, Jun 27, 2017 3:00:00 PM, Continue reading at the source
Option Market Alert: Esperion Therapeutics Inc Implied Price Swing Hits An ... CML News - Jun 25, 2017 No Risk Alert Here: Before we dive into any analysis we simply note that Esperion Therapeutics Inc (NASDAQ:ESPR) risk is neither elevated nor depressed. [...]
Sun, Jun 25, 2017 9:56:00 PM, Continue reading at the source
If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Motley Fool - Jun 22, 2017 After updating investors this week on its strategy for tackling the blockbuster market for cholesterol lowering drugs, shares in Esperion Therapeutics (NASDAQ:ESPR) are rocketing higher. Here's how the company plans to make its cholesterol-lowering ... [...]
Thu, Jun 22, 2017 7:41:00 PM, Continue reading at the source
Just the Facts on Esperion Therapeutics, Inc. (ESPR) StockNewsJournal - Jun 22, 2017 Esperion Therapeutics, Inc. (ESPR) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $41.02, up from yesterday's close by 19.21%. Esperion Therapeutics Inc. (ESPR) Soars 19.21% on June 21 - Equities.com Esperion Therapeutics, Inc. (ESPR) Receives Average Recommendation of “Buy ... - The Cerbat Gem [...]
Thu, Jun 22, 2017 7:41:00 PM, Continue reading at the source
Esperion Therapeutics Inc. (ESPR) Moves Lower on Volume Spike for June 16 Equities.com - Jun 16, 2017 Esperion Therapeutics Inc. (ESPR) traded on unusually high volume on Jun. 16, as the stock lost 3.39% to close at $33.39. On the day, Esperion Therapeutics Inc. saw 2.79 million shares trade hands on 5,148 trades. Considering that the stock averages ... KCG Holdings Inc. Purchases Shares of 39196 Esperion Therapeutics, Inc. (ESPR) - Markets Daily [...]
Fri, Jun 16, 2017 9:30:00 PM, Continue reading at the source
Commit To Purchase Esperion Therapeutics At $27, Earn 21.2% Annualized Using ... Nasdaq - May 31, 2017 Investors considering a purchase of Esperion Therapeutics Inc (Symbol: ESPR) shares, but tentative about paying the going market price of $31.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. [...]
Wed, May 31, 2017 4:30:00 PM, Continue reading at the source
Esperion Therapeutics, Inc. (ESPR) Receives Average Rating of “Buy” from ... Transcript Daily - May 15, 2017 Esperion Therapeutics logo Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned a consensus rating of “Buy” from the fourteen brokerages that are covering the stock, MarketBeat reports. [...]
Mon, May 15, 2017 2:03:00 PM, Continue reading at the source